Iain Dukes, D.Phil.

Chairman of the Board

Dr. Dukes joined the Iovance Board of Directors and was appointed Chairman of the Board in August 2016. Dr. Dukes is a Venture Partner at OrbiMed Advisors. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. He has also served as President and Chief Executive Officer, as well as a member of the Board of Directors of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes serves on the Board of Directors of Themis Biosciences, Ikena Oncology, KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ReViral Limited and ENYO Therapeutics. Dr. Dukes co-founded and is Chief Executive Officer of Theseus Pharmaceuticals, co-founded and serves on the Board of Directors of Kartos Therapeutics, and co-founded Telios Pharma, where he serves as President. He holds an M.J. and D.Phil. from the University of Oxford, an M.S. in Cardiovascular Studies from the University of Leeds, and a B.S. in Pharmacology from the University of Bath.

View more +

Committees

  • Nominating and Corporate Governance Committee
    Chair

Athena Countouriotis, M.D.

Director

Dr. Countouriotis is the President and Chief Executive Officer and a member of the Board of Directors of Turning Point Therapeutics. She has also served as the Chief Medical Officer for multiple public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier in her career, Dr. Countouriotis led development of products for Pfizer and Bristol-Myers Squibb, including Sutent®, Mylotarg™, Bosulif® and Sprycel®. Dr. Countouriotis also serves on the Board of Directors at Passage Bio. She holds an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine. Dr. Countouriotis received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology-Oncology Program.

View more +

Committees

  • Compensation Committee
    Member
  • Nominating and Corporate Governance Committee
    Member

Wendy Dixon, Ph.D.

Director

Dr. Dixon previously served as Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb (BMS) from 2001 to 2009. She led the global commercialization and launch strategy of eight new products and directed growth and life cycle management for in-line brands. As a member of the Executive Committee at BMS, she was deeply involved with the strategy and activities that transformed BMS into a highly successful specialty biopharmaceutical company. Dr. Dixon also established and served as the executive sponsor for the BMS “Women’s Affinity Network,” focused on gender diversity and inclusion priorities. From 1996 to 2001, Dr. Dixon was Senior Vice President, Marketing at Merck & Co., where she was responsible in launching six new products. Previously, Dr. Dixon held executive management positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. She currently serves on the board of directors of Alkermes Plc, Arvinas, Inc. and Black Diamond Therapeutics, Inc. Previously, Dr. Dixon served on the board of directors of Incyte Corporation, bluebird bio, Inc., Dentsply International, Furiex Pharmaceuticals, Orexigen Therapeutics, Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.), Ardea Biosciences, Inc. and Voyager Therapeutics, Inc. Dr. Dixon earned a B.Sc., an M.Sc. in Natural Science, and a Ph.D. in Biochemistry at the University of Cambridge, UK.

View more +

    Ryan Maynard

    Director

    Mr. Maynard recently served as the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked, from October 2019 to early 2022. He previously was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company. Mr. Maynard has served in various executive roles at Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company, including 10 years as Chief Financial Officer. Prior to joining Rigel, he served as Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, and Controller of General Magic, Inc. Mr. Maynard has held various positions at Siliconix, Inc., including Senior Finance Manager. He previously worked at Ernst and Young LLP. He holds a B.S. in Commerce–Accounting from Santa Clara University.

    View more +

    Committees

    • Audit Committee
      Chair

    Merrill A. McPeak

    Director

    General (Ret.) McPeak has extensive leadership experience in the military and as a member of public and private company boards of directors. He joined the Iovance Board of Directors in July 2011, and served as the interim Chief Executive Officer of Iovance from January 2013 until July 2013. General McPeak is currently the President of McPeak and Associates, a consulting firm that he founded in 1995. General McPeak previously served as a director of several public companies, including Tektronix, Inc., Trans World Airlines, Inc., and ECC International Corp., where he was for many years the Chairman of the Board. General McPeak has served as Director of Research Solutions, Inc., Aerojet Rocketdyne, Lilis Energy, Valence Surface Technologies and Navex Global. He was Chairman of the Board of Coast Plating, Inc., a privately held turnkey provider of metal processing and metal finishing services, from January 2009 until the company was acquired by Trive Capital and renamed Valence Surface Technologies. General McPeak helped found and served as Chairman of the Board of EthicsPoint, Inc., a provider of risk management and compliance software as a service that was acquired in 2012 and restyled Navex Global.

    From 1990 until his retirement from active military service in late 1994, General McPeak was Chief of Staff of the United States Air Force. As a member of the Joint Chiefs of Staff, General McPeak was a military advisor to the Secretary of Defense and the President of the United States. He received a B.A. in Economics from San Diego State College and an M.S. in International Relations from George Washington University and is a member of the Council on Foreign Relations. From July 2010 to December 2017, General McPeak was Chairman of the American Battlefield Monuments Commission.

    View more +

    Committees

    • Audit Committee
      Member
    • Compensation Committee
      Member
    • Nominating and Corporate Governance Committee
      Member

    Wayne Rothbaum

    Director

    Mr. Rothbaum is currently the President of Quogue Capital LLC, a life sciences investment fund he founded in 2001. Beginning in 2012, he served as the Co-founder and largest investor of Acerta Pharma B.V., a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. Acerta Pharma was sold to AstraZeneca in February 2016. From February 2013 until its sale in February 2016, Mr. Rothbaum served as the Executive Chairman of Acerta Pharma. He is also the Co-founder and Executive Chairman of Kartos Therapeutics and Telios Pharma. From 1993 to 2001, he led the biotechnology practice at the strategic consulting firm The Carson Group. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in Political Science and Psychology, and received an M.A. in International Affairs from George Washington University.

    View more +

    Committees

    • Compensation Committee
      Member

    Michael Weiser, M.D., Ph.D.

    Director

    Dr. Weiser is the Founder and a Principal of Actin Biomed LLC, a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm. Dr. Weiser previously served as the Chairman of the Board of Directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014. He also served on the Board of Directors of Emisphere Technologies, Inc., a pharmaceutical and drug delivery company, and Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received an M.D. from New York University School of Medicine, and completed a Ph.D. in Molecular Neurobiology at Cornell University Medical College.

    View more +

    Commitees

    • Compensation Committee
      Chair
    • Audit Committee
      Member
    • Nominating and Corporate Governance Committee
      Member
    See Our Research Partners & Collaborators